Golimumab is a human monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and uveitis.
It is used as an immunosuppressive drug and targets and inhibits TNF-alpha.
It is administered through intravenous infusion every 8 weeks or subcutaneously every month.
In 2016, it sold €120 million in Europe.
It has an immunogenicity rate of 2-15%.
Labs that test for drug level:
Labs that test for ADA titre: